# L9LS MAb in Malian Infants

> **NCT06461026** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 180 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** L9LS
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT06461026
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-19
- **Primary completion:** 2025-06-27
- **Final completion:** 2026-06
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06461026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06461026, "L9LS MAb in Malian Infants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06461026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*